Lori Daane, PhD joins Bionique as its new CSO effective April 1, 2024. She has over thirty years of experience and is uniquely positioned to lead Bionique’s service portfolio expansion, enabling the organization to solve for the biosafety testing needs associated with the development, manufacturing, and release of biologics inclusive of cell & gene therapies.
